Ultragenyx to Sell Priority Review Voucher for $203 Million
Ultragenyx Pharmaceutical said it is selling a rare pediatric disease priority review voucher for $203 million.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Ultragenyx to Sell FDA Priority Review Voucher for $203 Million
Ultragenyx entered an asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $203 million in cash at closing. The voucher was awarded after FDA approval of FAYUVI (UX111) for MPS IIIA. The transaction is subject to customary conditions.
Ultragenyx to sell rare pediatric disease priority review voucher for $203 million
Ultragenyx signed a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for USD 203 million. The voucher was awarded on FDA clearance of FAYUVI (UX111) for mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome Type A. Closing remains subject to customary conditions, including expi
Ultragenyx agrees to sell priority review voucher for $203 million
Ultragenyx entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher for $203 million.